FDA Approves Oxford Brain Diagnostics' Novel MRI Software for Neurodegeneration Assessment
Oxford Brain Diagnostics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for CDM Insights, a software powered by its proprietary Cortical Disarray Measurement (CDM®) technology. This approval enables trained healthcare professionals to assess clinical brain health using MRI scans, particularly for neurodegenerative conditions such as Alzheimer’s disease.
CDM Insights offers a detailed analysis of the brain’s microstructure, providing clinicians with advanced tools to detect subtle changes associated with neurodegeneration.
The technology enhances understanding of cortical microstructure, aiding early detection and supporting more informed decision-making in patient care.
By offering insights into brain structure changes before symptom progression, it aims to improve patient outcomes and provide greater clarity for both clinicians and caregivers.
The software introduces new measures of microstructure and cortical thickness that were previously unavailable in the US market.
These features support early detection of neurodegenerative disorders while also providing standard macrostructural measurements.
CDM Insights is a cloud-native and non-invasive solution that tracks brain changes across different stages of adult life. It processes clinical MRI scan data from both 1.5T and 3T scanners, generating outputs as images and numerical values, typically represented as percentiles within a normative population distribution.
The software will be accessible to healthcare facilities across the US and is intended for use by neurologists, radiologists, and other trained professionals experienced in the post-processing of MRI data.
CDM Insights is designed to assist in clinical assessments but is not intended to be used in isolation for diagnostic or treatment decisions. The final responsibility for diagnosis and treatment remains with the physician.